The Company will host a conference call to discuss the results at 11:00 am
Eastern Daylight Time on July 25, 2001. Participating in the conference call
will be:
R. David Yost, Chairman & Chief Executive Officer
Kurt J. Hilzinger, President & Chief Operating Officer
George L. James, III, Chief Financial Officer
The dial in numbers for the live call will be as follows:
800/230-1085 from within the United States. No access code required.
651/224-7472 from outside the United States. No access code required.
In order to ensure the widest distribution possible, the Company will be
broadcasting the conference call over the Internet. The call will be accessible
through Street Events, www.streetevents.com, and also through AmeriSource's web
site, www.amerisource.com. Users are encouraged to log on to the webcast
approximately 15 minutes in advance of the scheduled start time of the call.
Following the live call, replays will be made available on the Internet and via
telephone. A replay of the webcast will be posted on www.amerisource.com
approximately two hours after the completion of the call and will remain
available for thirty days. To access the telephone replay, from within the US
dial 800/475-6701. From outside the US, dial 320/365-3844.
The access code is 593131. The telephone replay will be available from 2:30 p.m.
EST on 7/25/01 to 11:59 p.m. on 8/1/01.
About AmeriSource
AmeriSource Health Corporation, with more than $14 billion in annualized
operating revenue, is a leading distributor of pharmaceutical and related
healthcare products and services, and the industry's largest provider of
pharmaceuticals to acute care/health systems customers.
Headquartered in Valley Forge, PA, the Company serves its base of about 15,000
customer accounts through a national network of 22 strategically located drug
distribution facilities. For news and additional information about the company,
visit its web site at www.amerisource.com.
Certain information contained in this press release includes forward-looking
statements (as defined in Section 27A of the Securities Act and Section 21E of
the Exchange Act) that reflect the Company's current views with respect to
future events and financial performance.
Certain factors such as competitive pressures, success of restructuring or
systems initiatives, market interest rates, regulatory changes, continued
industry consolidation, changes in customer mix, changes in pharmaceutical
manufacturers' pricing and distribution policies, changes in U.S. government
policies, customer insolvencies, the loss of one or more key customer or
supplier relationships and other matters contained in the Company's 10-K for
fiscal year 2000 and other public documents could cause actual results to differ
materially from those in the forward-looking statements.
The company assumes no obligation to update the matters discussed in this press
release.
Additional Information About The Merger
In connection with their proposed merger, AmeriSource-Bergen, together with
AmeriSource and Bergen Brunswig, filed a joint proxy statement/prospectus with
the Securities and Exchange Commission. INVESTORS AND SECURITY HOLDERS ARE
ADVISED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE,
BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION.
Investors and security holders may obtain a free copy of the joint proxy
statement/prospectus (when available) and other documents filed by
AmeriSource-Bergen (as well as by AmeriSource and Bergen Brunswig) at the SEC's
web site at www.sec.gov.
The joint proxy statement/prospectus and such other documents may also be
obtained for free from AmeriSource or from Bergen Brunswig by directing such
request to AmeriSource Health Corporation, General Counsel, 1300 Morris Drive,
Suite 100, Chesterbrook, Pennsylvania 19087-5594, telephone: 610/727-7000; or to
Bergen Brunswig Corporation, Attention: Corporate Secretary, 4000 Metropolitan
Drive, Orange, California 92868-3510, Telephone: 714/385-4000.
AmeriSource and Bergen Brunswig and their respective directors, executive
officers and other members of their management and employees may be deemed to be
participants in the solicitation of proxies from their respective stockholders
in connection with the proposed merger.
Information concerning AmeriSource's participants in the solicitation is set
forth in AmeriSource's Current Report on Form 8-K filed with the Securities and
Exchange Commission on March 19, 2001, and information concerning Bergen
Brunswig's participants in the solicitation is set forth in Bergen Brunswig's
Current Report on Form 8-K filed with the Securities and Exchange Commission on
March 19, 2001.
CONTACT:
AmeriSource Health Corporation, Valley Forge
Michael N. Kilpatric, 610/727-7118
mkilpatric@amerisource.com